Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery and development of orexin receptor antagonists as therapeutics for insomnia
Christopher J. Winrow, John J. Renger
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 283-293
Open Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Pharmacological Reviews (2018) Vol. 70, Iss. 2, pp. 197-245
Open Access | Times Cited: 306
Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Leslie Citrome
International Journal of Clinical Practice (2014) Vol. 68, Iss. 12, pp. 1429-1441
Open Access | Times Cited: 246
Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant
Jie Yin, Juan Carlos Mobarec, Peter Kolb, et al.
Nature (2014) Vol. 519, Iss. 7542, pp. 247-250
Closed Access | Times Cited: 203
The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
Chunmei Wang, Qinqin Wang, Bingyuan Ji, et al.
Frontiers in Molecular Neuroscience (2018) Vol. 11
Open Access | Times Cited: 163
Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You?
Flavio Ballante, Albert J. Kooistra, Stefanie Kampen, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 4, pp. 1698-1736
Open Access | Times Cited: 104
Orexin/hypocretin receptor signalling cascades
Jyrki P. Kukkonen, Christopher S. Leonard
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 314-331
Open Access | Times Cited: 180
Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors
Jie Yin, Kerim Babaoglu, Chad A. Brautigam, et al.
Nature Structural & Molecular Biology (2016) Vol. 23, Iss. 4, pp. 293-299
Closed Access | Times Cited: 132
Orexin/hypocretin receptor signalling: a functional perspective
Christopher S. Leonard, Jyrki P. Kukkonen
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 294-313
Open Access | Times Cited: 126
Orexins and stress
Laura A. Grafe, Seema Bhatnagar
Frontiers in Neuroendocrinology (2018) Vol. 51, pp. 132-145
Open Access | Times Cited: 106
Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies
Elena Urrestarazu, Jorge Iriarte
Nature and Science of Sleep (2016), pp. 21-21
Open Access | Times Cited: 102
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development
Jennifer Kricker, Clive P. Page, Fridrik Runar Gardarsson, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 4, pp. 1404-1433
Open Access | Times Cited: 58
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
Suvorexant in insomnia: efficacy, safety and place in therapy
Danielle N. Rhyne, Sarah L. Anderson
Therapeutic Advances in Drug Safety (2015) Vol. 6, Iss. 5, pp. 189-195
Open Access | Times Cited: 74
Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia
Pascal Bonaventure, Jonathan Shelton, Sujin Yun, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 354, Iss. 3, pp. 471-482
Open Access | Times Cited: 71
Orexin/hypocretin neuron activation is correlated with alcohol seeking and preference in a topographically specific manner
David E. Moorman, Morgan H. James, Elisabeth A. Kilroy, et al.
European Journal of Neuroscience (2016) Vol. 43, Iss. 5, pp. 710-720
Open Access | Times Cited: 67
The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice
Marcelo F. Lopez, David E. Moorman, Gary Aston‐Jones, et al.
Brain Research (2016) Vol. 1636, pp. 74-80
Open Access | Times Cited: 66
Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA
Ryoji Suno, Kanako Kimura, Takanori Nakane, et al.
Structure (2017) Vol. 26, Iss. 1, pp. 7-19.e5
Open Access | Times Cited: 66
Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats
Robyn M. Brown, Andrezza K. Kim, Shaun Yon‐Seng Khoo, et al.
Addiction Biology (2015) Vol. 21, Iss. 3, pp. 603-612
Open Access | Times Cited: 64
Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases
Alain Couvineau, Thierry Voisin, Pascal Nicole, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 63
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Exploring triazole-based drugs: Synthesis, application, FDA approvals, and clinical trial updates–A comprehensive review
Javed Khan, Anjali Rani, M. Aslam, et al.
Tetrahedron (2024) Vol. 162, pp. 134122-134122
Closed Access | Times Cited: 7
Understanding the Sleep-Wake Cycle: Sleep, Insomnia, and the Orexin System
Andrew D. Krystal, Ruth M. Benca, Thomas S. Kilduff
The Journal of Clinical Psychiatry (2013) Vol. 74, Iss. suppl 1, pp. 3-20
Open Access | Times Cited: 66
Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism
Christine Dugovic, Jonathan Shelton, Sujin Yun, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 64
OX1 and OX2 orexin/hypocretin receptor pharmacogenetics
Miles D. Thompson, Henri Xhaard, Takeshi Sakurai, et al.
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 61
Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?
Craig M. Smith, Andrew W. Walker, Ihaia T. Hosken, et al.
Frontiers in Pharmacology (2014) Vol. 5
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top